Literature DB >> 23295023

Effect of dihydropyridine calcium channel blockers and glucocorticoids on the prevention and development of scleroderma renal crisis in an Italian case series.

Gaia Montanelli1, Lorenzo Beretta, Alessandro Santaniello, Raffaella Scorza.   

Abstract

OBJECTIVES: Scleroderma renal crisis (SRC) is a relative rare yet dramatic event in the history of systemic sclerosis (SSc). Several factors that may precipitate or protect from the development of SRC have been described in previous case-control studies. To date, no attempt has been made to evaluate these factors in an observational fashion.
METHODS: Retrospective data from 410 SSc patients with disease duration <5 years at referral were evaluated in an observational fashion for the development of hypertensive or normotensive SRC within 5 years from the first visit at our centre. Baseline characteristics as well as the use of steroids or dhiydropyridine calcium-channel blockers (CCB) were analysed via the Cox regression method with time-dependent covariates.
RESULTS: In the multivariate model the diffuse subset the disease (HR=5.728 CI(95)=2.199-14.918, p<0.001) and the use of prednisone (HR=1.015, CI(95)=1.004-1.026, p=0.006) resulted to be predictors for the development of SRC, with a risk to develop SRC increased by 1.5% for every mg of prednisone/day consumed the trimester prior SRC. Contrariwise, the risk to develop SRC was highly reduced in those who were prescribed CCBs (HR=0.094, CI(95)=0.038-0.236, p<0.001).
CONCLUSIONS: Steroids exhibits a weak effect on the risk to progress toward SRC in our case series, whilst dhyidrophyridines CCB appeared to be protective against that. Further larger prospective studies are warranted to better define the role of CCB in this setting or as a background therapy for SSc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23295023

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  6 in total

Review 1.  [Systemic sclerosis : What is currently available for treatment?]

Authors:  M O Becker
Journal:  Internist (Berl)       Date:  2016-12       Impact factor: 0.743

Review 2.  Scleroderma renal crisis and renal involvement in systemic sclerosis.

Authors:  Thasia G Woodworth; Yossra A Suliman; Wendi Li; Daniel E Furst; Philip Clements
Journal:  Nat Rev Nephrol       Date:  2016-09-19       Impact factor: 28.314

Review 3.  Systemic sclerosis: a systematic review on therapeutic management from 2011 to 2014.

Authors:  Amber Young; Dinesh Khanna
Journal:  Curr Opin Rheumatol       Date:  2015-05       Impact factor: 5.006

4.  Mistaken identity: normotensive scleroderma renal crisis.

Authors:  Arwa Aburizik; Siddharth Singh; Laith Al-Rabadi; Christopher Blosser
Journal:  BMJ Case Rep       Date:  2014-05-29

5.  Systemic sclerosis medications and risk of scleroderma renal crisis.

Authors:  S M Gordon; J B Hughes; R Nee; R S Stitt; W T Bailey; D J Little; J D Edison; S W Olson
Journal:  BMC Nephrol       Date:  2019-07-25       Impact factor: 2.388

Review 6.  Kidney Involvement in Systemic Sclerosis.

Authors:  Francesco Reggiani; Gabriella Moroni; Claudio Ponticelli
Journal:  J Pers Med       Date:  2022-07-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.